ARA-290 (also known as Cibinetide) is an 11–amino acid peptide derived from erythropoietin (EPO). Unlike full-length EPO, which stimulates red blood cell production, ARA-290 is engineered to selectively bind the innate repair receptor (IRR) without affecting the erythropoietin receptor responsible for erythropoiesis. This makes it a promising research peptide for anti-inflammatory, neuroprotective, and tissue repair applications. ARA-290 remains experimental and is not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Investigated for reducing neuropathic pain in models of sarcoidosis and diabetes.
- Studied for anti-inflammatory and tissue repair effects through IRR signaling.
- Explored in vascular research for improving endothelial function and microcirculation.
- Examined in autoimmune and inflammatory disease models for protective effects without stimulating red blood cell production.
Proposed Uses (Research Areas)
- Neuropathic pain research (e.g., small fiber neuropathy, diabetic neuropathy).
- Inflammation and immune modulation studies.
- Vascular and endothelial function research.
- Neuroprotection and regenerative medicine models.
How It Is Dosed in Research Settings
- Injectable: Clinical research has studied subcutaneous injections at 2–4 mg daily or several times per week.
- Cycle length: Human trials have extended from 4 weeks to 6 months depending on endpoints (pain, inflammation, vascular health).
- Handling: Supplied as lyophilized powder or pre-formulated solution; reconstituted with bacteriostatic water and stored refrigerated per research SOPs.
Important Considerations
- Regulatory status: ARA-290 is not FDA-approved; it remains under investigation in clinical research.
- Evidence base: Early clinical trials suggest benefit in neuropathic pain and inflammatory disorders, but large-scale studies are still needed.
- Safety: Generally well tolerated in trials, with mild side effects such as injection site reactions or transient fatigue. Unlike EPO, it does not raise hematocrit or hemoglobin levels.
Disclaimer
This material is provided for educational purposes only and summarizes published research on ARA-290.
It is not medical advice. ARA-290 is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.